Have severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
Has a known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or T-DM1 or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
COHORT 1: Hypersensitivity to pembrolizumab or any of its excipients
COHORT 2: Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients.
Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients
Known hypersensitivity to any component of PVX-410, Hiltonol, Montanide, pembrolizumab, or excipients
Has severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to ipilimumab and/or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
History of allergic reactions or hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients
Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its recipients
Hypersensitivity to pembrolizumab or any of its excipients
Has participated in any other pembrolizumab trial and has been treated with pembrolizumab.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Patient has a known hypersensitivity to any of the excipients of bavituximab or pembrolizumab or monoclonal antibody
Hypersensitivity to pembrolizumab or any of its excipients
Has serious hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
Hypersensitivity to pembrolizumab or sunitinib or any of their excipients
Has hypersensitivity to pembrolizumab, epacadostat or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or lenvatinib or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (>= grade 3) to pembrolizumab or any of its excipients.
Has severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients
Had a severe hypersensitivity reaction to treatment with pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or paricalcitol or any of its excipients.
Has hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients
Has a known history of hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to PBZ or any of its excipients
Hypersensitivity to pembrolizumab or any of its recipients
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to either study drug or any of the excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has known hypersensitivity to pembrolizumab and/or epacadostat or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to BGB324, pembrolizumab, or any of their excipients.
Hypersensitivity to ibrutinib or pembrolizumab or any of their excipients
Severe hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients
History of hypersensitivity to pembrolizumab, docetaxel, gemcitabine, pemetrexed or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or lanreotide or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known or presumed hypersensitivity to decitabine or pembrolizumab (or any of their excipients)
Hypersensitivity to pembrolizumab or ibrutinib or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to bevacizumab, cyclophosphamide, pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, azacitidine, mannitol, or any of their excipients
Has a known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, vorinostat or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab, docetaxel or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (?Grade 3) to pembrolizumab, MK-4280, or lenvatinib and/or any of its excipients
Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab
REGISTRATION TO TREATMENT (STEP 1): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients
REGISTRATION TO TREATMENT (STEP 2): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or epacadostat or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, epacadostat or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to MK-3475 (pembrolizumab) or any of its excipients;
Hypersensitivity to pembrolizumab, binimetinib, or any excipients of either drug
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL-2 or any component of the formulation
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
Prior known allergic reaction to pembrolizumab or its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity (> Grade 3) to pembrolizumab, its active substance and/or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity to pembrolizumab, its active substance and/or any of its excipients
Known hypersensitivity to pembrolizumab or any of its insipients
Severe hypersensitivity to any pembrolizumab excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients and/or liposomal doxorubicin
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has known hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients.
Known allergy to pembrolizumab or any of its excipients.
Has severe hypersensitivity (? Grade 3) to any study treatment (pembrolizumab, cisplatin, or 5-FU) and/or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (Grade ?3) to pembrolizumab and/or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, imatinib, or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Prior pembrolizumab
Hypersensitivity to pembrolizumab or any of it's excipients.
Hypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Patients with known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients, or to any of the study chemotherapy agents and/or to any of their excipients.
Patients must not have a hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to the active substance or to any of the excipients in BV or pembrolizumab.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients